|

Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD

RECRUITINGPhase 2Sponsored by University of Alberta
Actively Recruiting
PhasePhase 2
SponsorUniversity of Alberta
Started2025-06-05
Est. completion2026-12-31
Eligibility
Age50 Years – 85 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06969573

Summary

The goal of this clinical trial is to evaluate the impact of inhaled Treprostinil on breathlessness and low exercise capacity in patients living with mild chronic obstructive pulmonary disease. Participants will be asked to: * Perform lung function and exercise tests * Have ultrasound of their heart * Have CT images of their lungs * Visit the lab on 5 different occasions (plus one visit to the CT imaging clinic) The researchers will compare the effectiveness and feasibility of inhaled Treprostinil to improve breathlessness upon exertion and exercise capacity

Eligibility

Age: 50 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients with mild COPD (defined as having a postbronchodilator FEV1/FVC ratio \<0.70 and FEV1 ≥ 80% predicted

Exclusion Criteria:

* Pre-existing heart failure and pulmonary artery hypertension.
* Known thrombocytopenia.
* Resting blood pressure of \<90mmHg systolic and \<50 mmHg diastolic.
* Known sensitivity to prostanoids
* Severe hepatic insufficiency

Conditions2

COPDCOPD - Chronic Obstructive Pulmonary Disease

Browse More Trials

COPD trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.